# A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

> **NCT02828124** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 25 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** BMS-986183
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02828124
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-23
- **Primary completion:** 2018-01-08
- **Final completion:** 2018-01-08
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02828124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02828124, "A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02828124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*